Cargando…

Management of urticaria in COVID‐19 patients: A systematic review

The global pandemic COVID‐19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature, and present our findings. Allowing P...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuelgasim, Eyad, Dona, Ann Christine Modaragamage, Sondh, Rajan Singh, Harky, Amer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536947/
https://www.ncbi.nlm.nih.gov/pubmed/32986289
http://dx.doi.org/10.1111/dth.14328
_version_ 1783590633886187520
author Abuelgasim, Eyad
Dona, Ann Christine Modaragamage
Sondh, Rajan Singh
Harky, Amer
author_facet Abuelgasim, Eyad
Dona, Ann Christine Modaragamage
Sondh, Rajan Singh
Harky, Amer
author_sort Abuelgasim, Eyad
collection PubMed
description The global pandemic COVID‐19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature, and present our findings. Allowing PRISMA guidelines, a comprehensive literature search was carried out with Medline, EMBASE, Scopus, Cochrane, and Google Scholar, using key MeSH words, which include “COVID‐19,” “Coronavirus,” “SARS‐Cov‐2,” “Urticaria,” “Angioedema,” and “Skin rash” up to 01 August 2020. The key inclusion criteria were articles that reported on urticaria and/or angioedema due to COVID‐19 infection and reported management and outcome. Studies were excluded if no case or cohort outcomes were observed. Our search returned 169 articles, 25 of which met inclusion criteria. All studies were case reports, reporting 26 patients with urticaria and/or angioedema, COVID‐19 infection and their management and/or response. ajority of patients (n = 16, 69%) were over 50 years old. However, urticaria in the younger ages was not uncommon, with reported case of 2 months old infant. Skin lesions resolved from less than 24 hours to up to 2 weeks following treatment with antihistamines and/or steroids. There have been no cases of recurrent urticaria or cases nonresponsive to steroids. Management of urticarial in COVID‐19 patients should involve antihistamines. Low dose prednisolone should be considered on an individualized basis. Further research is required in understanding urticarial pathogenesis in COVID‐19. This will aid early diagnostic assessment in patients with high index of suspicion and subsequent management in the acute phase.
format Online
Article
Text
id pubmed-7536947
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-75369472020-10-07 Management of urticaria in COVID‐19 patients: A systematic review Abuelgasim, Eyad Dona, Ann Christine Modaragamage Sondh, Rajan Singh Harky, Amer Dermatol Ther Review Articles The global pandemic COVID‐19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature, and present our findings. Allowing PRISMA guidelines, a comprehensive literature search was carried out with Medline, EMBASE, Scopus, Cochrane, and Google Scholar, using key MeSH words, which include “COVID‐19,” “Coronavirus,” “SARS‐Cov‐2,” “Urticaria,” “Angioedema,” and “Skin rash” up to 01 August 2020. The key inclusion criteria were articles that reported on urticaria and/or angioedema due to COVID‐19 infection and reported management and outcome. Studies were excluded if no case or cohort outcomes were observed. Our search returned 169 articles, 25 of which met inclusion criteria. All studies were case reports, reporting 26 patients with urticaria and/or angioedema, COVID‐19 infection and their management and/or response. ajority of patients (n = 16, 69%) were over 50 years old. However, urticaria in the younger ages was not uncommon, with reported case of 2 months old infant. Skin lesions resolved from less than 24 hours to up to 2 weeks following treatment with antihistamines and/or steroids. There have been no cases of recurrent urticaria or cases nonresponsive to steroids. Management of urticarial in COVID‐19 patients should involve antihistamines. Low dose prednisolone should be considered on an individualized basis. Further research is required in understanding urticarial pathogenesis in COVID‐19. This will aid early diagnostic assessment in patients with high index of suspicion and subsequent management in the acute phase. John Wiley & Sons, Inc. 2020-10-09 2021 /pmc/articles/PMC7536947/ /pubmed/32986289 http://dx.doi.org/10.1111/dth.14328 Text en © 2020 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Abuelgasim, Eyad
Dona, Ann Christine Modaragamage
Sondh, Rajan Singh
Harky, Amer
Management of urticaria in COVID‐19 patients: A systematic review
title Management of urticaria in COVID‐19 patients: A systematic review
title_full Management of urticaria in COVID‐19 patients: A systematic review
title_fullStr Management of urticaria in COVID‐19 patients: A systematic review
title_full_unstemmed Management of urticaria in COVID‐19 patients: A systematic review
title_short Management of urticaria in COVID‐19 patients: A systematic review
title_sort management of urticaria in covid‐19 patients: a systematic review
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536947/
https://www.ncbi.nlm.nih.gov/pubmed/32986289
http://dx.doi.org/10.1111/dth.14328
work_keys_str_mv AT abuelgasimeyad managementofurticariaincovid19patientsasystematicreview
AT donaannchristinemodaragamage managementofurticariaincovid19patientsasystematicreview
AT sondhrajansingh managementofurticariaincovid19patientsasystematicreview
AT harkyamer managementofurticariaincovid19patientsasystematicreview